Saba Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Saba Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250,000	Closed	-$33.6K	–	296
2024 Q4	$33.6K	Hold	250,000	–	–	﹤0.01%	202
2024 Q3	$29.3K	Hold	250,000	–	–	﹤0.01%	240
2024 Q2	$30.1K	Hold	250,000	–	–	﹤0.01%	269
2024 Q1	$35.8K	Hold	250,000	–	–	﹤0.01%	274
2023 Q4	$44.4K	Hold	250,000	–	–	﹤0.01%	331
2023 Q3	$57.5K	Hold	250,000	–	–	﹤0.01%	367
2023 Q2	$47.8K	Hold	250,000	–	–	﹤0.01%	417
2023 Q1	$41.3K	Buy	+250,000	New	+$38.9K	﹤0.01%	565

Saba Capital Management's BLACR Position: Q1 2025 in Review

Saba Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 250,000 shares — an estimated $33.6K sold.

Saba Capital Management first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $57.5K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Saba Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Saba Capital Management sold 250,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $33.6K.
Saba Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Saba Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $57.5K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Saba Capital Management's 13F filing for Q1 2025, filed 15 May 2025.